Pay in 4 interest-free payments of $6.24 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
TRIUMPH-3: Weight management in people with cardiovascular disease Additional TRIUMPH Trials: Type 2 diabetes management Chronic low back pain Metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH/NAFLD) Cardiovascular and renal outcomes The TRIUMPH program has enrolled more than 5,800 participants total, making it one of the largest Phase 3 programs for an obesity medication in history
414518) on its cardiac drug Vymada, marketed internationally as Entresto widely prescribed for hypertension and heart failure
Typically, costs range between $1000-$1500 per month as a self-paying patient
Saxenda recorded a domestic sale of 42.4 billion won ($32.4 million) in the first three quarters of 2022, dominating the market with a 34.4 percent share
US$ 23.92
US$ 21.16
US$ 24.28
US$ 28.63
US$ 29.80
